Choi, Min Jeong Oh, Da Won Jang, Jae Wan Cho, Yong Seo Seo, Seon Hee Jeong, Kyu Sung Ko, Soo Young Pae, Ae Nim 2024-01-20T17:00:36Z 2024-01-20T17:00:36Z 2021-09-04 2011-06-20 0253-2964 https://pubs.kist.re.kr/handle/201004/130255 A series of isoxazol-indolin-2-one was designed for GSK-3 beta inhibitors as novel anticancer agents based on their binding mode analysis in GSK-3 beta crystal structure. Total 21 compounds were synthesized and evaluated for their inhibitory activity against two tumor cell lines (DU145 and HT29). Most of the synthesized compounds were potent with above 80% inhibitory activity at 100 mu M, and several compounds were examined for inhibitory activity against GSK-3 beta. Among them, 15(Z) (R(1)=H, R(2)=3-Cl-phenyl) was most active with 78% inhibition of tumor cell line (HT29) at 20 mu M and 72% inhibition of GSK-3 beta at 20 mu M. English KOREAN CHEMICAL SOC GLYCOGEN-SYNTHASE KINASE-3-BETA CANCER CELLS PANCREATIC-CANCER ACTIVATION APOPTOSIS Synthesis and Biological Evaluation of Novel GSK-3 beta Inhibitors as Anticancer Agents Article 10.5012/bkcs.2011.32.6.2015 1 BULLETIN OF THE KOREAN CHEMICAL SOCIETY, v.32, no.6, pp.2015 - 2020 BULLETIN OF THE KOREAN CHEMICAL SOCIETY 32 6 2015 2020 scie scopus kci ART001558895 000292117700032 2-s2.0-79959398638 Chemistry, Multidisciplinary Chemistry Article GLYCOGEN-SYNTHASE KINASE-3-BETA CANCER CELLS PANCREATIC-CANCER ACTIVATION APOPTOSIS Glycogen synthase kinase 3 beta inhibitor Isoxazol-indolin-2-one Anticancer